When Roche yesterday announced its $5.7 billion hostile takeover bid for Illumina, reactions on Twitter were varied and swift, ranging from the humorous — like Stuart Glenn's depiction of what a potential acquisition might be like — to the concerned — "If Roche plans to do to DNA sequencing what it did to PCR, then a lot of genomicists are